Labcorp Holdings Inc.
$367.13-$1.75 (-0.5%)
Last close · Data as of Nov 20, 2026
- Market cap
- $21.4B
- P/E
- 24.4x
- EV / EBITDA
- 13.6x
- Revenue
- $14.0B
- Net margin
- 6.3%
- ROCE
- 9.4%
Price chart
Technical chartScreen technicals →+40.4% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- +13.6%
- 3M
- +10.3%
- 6M
- +42.6%
- 1Y
- +40.4%
- 5Y
- +50.8%
52-week range
Day change -$1.75 (-0.5%) from $369 to $367 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in LH, bought on each weekday since 2021.
News & filings
What Labcorp Holdings filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockStrengthThe price is 24.5% above its 200-day average, and the 50-day average is above the 200-day.
Concerns (1)
- Net profit fell 11.8% a year over three years.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services.
Read moreShow less
Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, the company offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI-enabled Test Selection, a generative AI-enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. The company has a strategic collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics. The company was founded in 1995 and is headquartered in Burlington, North Carolina.
- Sector
- Healthcare
- Shares outstanding
- 82.2M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $21.4B
- P/E
- 24.4x
- P/B
- 2.5x
- EV / EBITDA
- 13.6x
- EV / Sales
- 2.0x
- P/S
- 1.5x
- 52-week high
- $372.46
- 52-week low
- $250.39
Profitability
- Operating margin
- 10.9%
- Net margin
- 6.3%
- EBITDA margin
- 14.4%
- ROE
- 10.2%
- ROCE
- 9.4%
- ROA
- 4.8%
- Asset turnover
- 0.76
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $14.0B
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 7.2%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 5.6%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 17.5%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $1.2B
Solvency
- Current ratio
- 1.42
- Debt / Equity
- 0.76
- Debt / Assets
- 0.35
- CFO / Net profit
- 1.87
- Cash / Market cap
- 2.5%
Where the revenue went
Of every $100 of FY2025 revenue, $6 was left as net income.
| From | To | Amount |
|---|---|---|
| Revenue | Cost of revenue | $9.9B |
| Revenue | Gross profit | $4.0B |
| Gross profit | Selling, general and administrative | $2.2B |
| Gross profit | Other operating expenses | $280.0M |
| Gross profit | Operating income | $1.5B |
| Operating income | Pretax income | $1.1B |
| Operating income | Interest and other expense | $408.7M |
| Pretax income | Tax and other | $231.0M |
| Pretax income | Net income | $876.5M |
Revenue and net profit
Revenue grew 7.2% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $11.9B | $1.3B |
| FY2023 | $12.2B | $418.0M |
| FY2024 | $13.0B | $746.0M |
| FY2025 | $14.0B | $876.5M |
Cash flows
FY2025: $1.6B from operations, $1.2B free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | $2.0B | $1.5B |
| FY2023 | $1.3B | $874.1M |
| FY2024 | $1.6B | $1.1B |
| FY2025 | $1.6B | $1.2B |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $14.0B+7.2%1Y
- EBITDA
- $2.0B+11.1%1Y
- Net profit
- $876.5M+17.5%1Y
- Cash from operations
- $1.6B+3.4%1Y
- Free cash flow
- $1.2B+10.0%1Y
- Revenue CAGR, 3Y
- 5.6%
- Net profit CAGR, 3Y
- -11.8%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $14.0B | $2.0B | $876.5M | $1.2B | 10.2% | +7.2% | +17.5% |
Monthly returns
Month-by-month returns of LH across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $18.4B |
| Current assets | $4.0B |
| Non-current assets | $14.4B |
| Liabilities | $9.8B |
| Current liabilities | $2.8B |
| Non-current liabilities | $6.9B |
| Equity | $8.6B |
| Paid-in capital | $0.00 |
| Retained earnings | $8.6B |
| Minority interest | $16.9M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; LH highlighted.
P/E against peers
LH trades at 24.4x earnings against a peer median of 21.9x (a 12% premium).
Not shown (no positive earnings and no EV / Sales): Insmed Incorporated, Moderna, Inc., Viatris Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Labcorp Holdings Inc.LHthis companyP/E ↑ premium | $21.4B | 24.4x | 2.5x | 10.2% | 13.6x |
| Mettler-Toledo International Inc.MTD | $23.9B | 27.4x | — | -3676.8% | 20.9x |
| Insmed IncorporatedINSM | $22.7B | -17.8x | 30.8x | -172.8% | — |
| West Pharmaceutical Services, Inc.WST | $22.4B | 45.4x | 7.1x | 15.5% | 28.4x |
| Quest Diagnostics IncorporatedDGX | $21.7B | 21.9x | 3.0x | 13.8% | 12.9x |
| STERIS plcSTE | $20.7B | 26.5x | 2.9x | 10.9% | 14.0x |
| Moderna, Inc.MRNA | $20.5B | -7.3x | 2.4x | -32.6% | -7.5x |
| Incyte CorporationINCY | $20.2B | 15.7x | 3.9x | 24.9% | 9.8x |
| Viatris Inc.VTRS | $18.5B | — | 1.3x | -23.9% | — |
| Peer median | — | 21.9x | 3.0x | -6.5% | 13.5x |
Year-to-date ROI
LH since 1 January, against earlier years.
Historical volatility
LH's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | 14.8% |
| FY2023 | 9.2% |
| FY2024 | 8.7% |
| FY2025 | 10.9% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $14.0B |
| Cost of revenueCost Of Revenue | $9.9B |
| Gross profitGross Profit | $4.0B |
| Operating expensesOperating Expense | $2.5B |
| Selling, general and administrativeSelling General And Administration | $2.2B |
| Depreciation and amortisationDepreciation And Amortization In Income Statement | $280.0M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement | $280.0M |
| Amortization | $280.0M |
| Amortisation of intangiblesAmortization Of Intangibles Income Statement | $280.0M |
| Total expensesTotal Expenses | $12.4B |
| Operating incomeOperating Income | $1.5B |
| Interest and other | |
| Pretax incomePretax Income | $1.1B |
| TaxTax Provision | $229.8M |
| Net incomeNet Income | $876.5M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $18.4B |
| Current assetsCurrent Assets | $4.0B |
| Non-current assetsTotal Non Current Assets | $14.4B |
| LiabilitiesTotal Liabilities Net Minority Interest | $9.8B |
| Current liabilitiesCurrent Liabilities | $2.8B |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $6.9B |
| EquityTotal Equity Gross Minority Interest | $8.6B |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $1.6B |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $1.6B |
| Net income, continuing operationsNet Income From Continuing Operations | $877.7M |
| Depreciation and amortisationDepreciation And Amortization | $681.1M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $681.1M |
| Depreciation | $401.1M |
| Amortization cash flowAmortization Cash Flow | $280.0M |
| Amortization of intangiblesAmortization Of Intangibles | $280.0M |
| Stock-based compensationStock Based Compensation | $125.8M |
| Deferred taxDeferred Tax | $97.6M |
| Deferred income taxDeferred Income Tax | $97.6M |
| Gain loss on sale of businessGain Loss On Sale Of Business | — |
| Asset impairmentAsset Impairment Charge | $4.3M |
| Change in working capitalChange In Working Capital | -$526.1M |
| Other non-cash itemsOther Non Cash Items | $380.1M |
| Cash from discontinued operating activitiesCash From Discontinued Operating Activities | $0.00 |
| Investing cash flowInvesting Cash Flow | -$1.2B |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$1.2B |
| Capital expenditureCapital Expenditure | -$434.5M |
| Capital expenditure (reported)Capital Expenditure Reported | -$434.5M |
| AcquisitionsPurchase Of Business | -$582.0M |
| DisposalsSale Of Business | $6.9M |
| Net acquisitions and disposalsNet Business Purchase And Sale | -$575.1M |
| Purchase of investmentsPurchase Of Investment | -$192.4M |
| Sale of investmentsSale Of Investment | — |
| Net investment purchases and salesNet Investment Purchase And Sale | -$192.4M |
| Other investing changesNet Other Investing Changes | $8.0M |
| Cash from discontinued investing activitiesCash From Discontinued Investing Activities | $0.00 |
| Financing cash flowFinancing Cash Flow | -$1.5B |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$1.5B |
| Debt issuedIssuance Of Debt | $64.8M |
| Debt repaidRepayment Of Debt | -$1.1B |
| Net debt issuedNet Issuance Payments Of Debt | -$1.0B |
| Short-term debt issuedShort Term Debt Issuance | — |
| Short-term debt repaidShort Term Debt Payments | — |
| Net short-term debt issuedNet Short Term Debt Issuance | — |
| Long-term debt issuedLong Term Debt Issuance | $64.8M |
| Long-term debt repaidLong Term Debt Payments | -$1.1B |
| Net long-term debt issuedNet Long Term Debt Issuance | -$1.0B |
| Shares issuedIssuance Of Capital Stock | — |
| Common stock issuedCommon Stock Issuance | — |
| Net common stock issuedNet Common Stock Issuance | -$450.0M |
| Common stock repurchasedCommon Stock Payments | -$450.0M |
| Share buybacksRepurchase Of Capital Stock | -$450.0M |
| Stock options exercisedProceeds From Stock Option Exercised | $54.3M |
| Dividends paidCash Dividends Paid | -$240.7M |
| Common dividends paidCommon Stock Dividend Paid | -$240.7M |
| Other financing chargesNet Other Financing Charges | $179.4M |
| Cash from discontinued financing activitiesCash From Discontinued Financing Activities | $0.00 |
| Change in cashChanges In Cash | -$1.0B |
| Effect of exchange ratesEffect Of Exchange Rate Changes | 2,410.0% |
| Cash at the start of the yearBeginning Cash Position | $1.5B |
| Cash at the end of the yearEnd Cash Position | $532.3M |
| Free cash flowFree Cash Flow | $1.2B |
| Supplemental | |
| Other lines |
Learn while you research
Academy chapters picked for Labcorp Holdings Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 03 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 04 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read